Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.64 |
| ▸ | AHCY | P23526 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.54 |
| ▸ | PNP | P00491 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.54 |
| ▸ | HSPA8 | P11142 | 3/20 | 0.53 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GAPDH | P04406 | 1/20 | 0.47 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13835023 | 1.00 | ADORA3 (0.64) | ADORA3ADORA2AAHCYRXFP1LMNA | |
| SCHEMBL5982756 | 1.00 | ADORA3 (0.64) | ADORA3ADORA2AAHCYRXFP1LMNA | |
| SCHEMBL5982752 | 1.00 | ADORA3 (0.64) | ADORA3ADORA2AAHCYRXFP1LMNA | |
| SCHEMBL658006 | 0.88 | ADORA3 (0.67) | ADORA3ADORA2ARXFP1LMNATP53 | |
| SCHEMBL5982491 | 0.88 | ADORA3 (0.51) | ADORA3ADORA2ARXFP1LMNATP53 | |
| SCHEMBL5982465 | 0.88 | ADORA3 (0.67) | ADORA3ADORA2ARXFP1LMNATP53 | |
| SCHEMBL5982454 | 0.88 | ADORA3 (0.67) | ADORA3ADORA2ARXFP1LMNATP53 | |
| SCHEMBL658005 | 0.88 | ADORA3 (0.67) | ADORA3ADORA2ARXFP1LMNATP53 | |
| SCHEMBL5982489 | 0.88 | ADORA3 (0.51) | ADORA3ADORA2ARXFP1LMNATP53 | |
| SCHEMBL24420487 | 0.87 | ADORA3 (0.66) | ADORA3ADORA2ARXFP1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | claimed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| EP-4580609-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2025049632-A1 | COMPOSITIONS AND METHODS FOR BROAD DELIVERY OF RNA TO TISSUE | REJUVENATION TECHNOLOGIES INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024050372-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-4271389-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| US-20220347112-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. | 2022-11-03 | — | — | US | disclosed |
| WO-2022147039-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| US-20120295311-A1 | Methods and Materials for Nucleic Acid Manipulation | BASF SE (DE) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | ADORA3 4335/4885ADORA2A 3761/4885AHCY 1654/4885 |
| US-20220347112-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | TERT, PLTP, PCTP | ADORA3 4596/4885ADORA2A 4673/4885AHCY 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.